T. Rowe Price Associates
GOSS icon

T. Rowe Price Associates’s Gossamer Bio GOSS Stock Holding History

T. Rowe Price Associates’s Portfolio GOSS Stock Details GOSS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$44K Buy
132,026
+18,888
+17% +$29.7K ﹤0.01% 3077
2025
Q4 		$351K Buy
113,138
+12,480
+12% +$35.6K ﹤0.01% 2563
2025
Q3 		$265K Buy
100,658
+5,367
+6% +$11.8K ﹤0.01% 2662
2025
Q2 		$118K Buy
95,291
+30,514
+47% +$33.3K ﹤0.01% 2861
2025
Q1 		$72K Hold
64,777
– – ﹤0.01% 2879
2024
Q4 		$59K Sell
64,777
-6,369,269
-99% -$5.46M ﹤0.01% 2910
2024
Q3 		$6.35M Buy
6,434,046
+939,252
+17% +$904K ﹤0.01% 1233
2024
Q2 		$4.95M Buy
5,494,794
+2,603,789
+90% +$1.95M ﹤0.01% 1229
2024
Q1 		$3.41M Sell
2,891,005
-804,222
-22% -$885K ﹤0.01% 1340
2023
Q4 		$3.37M Buy
+3,695,227
New +$2.73M ﹤0.01% 1330
2023
Q3 		– Sell
-1,318,680
Closed -$1.58M – 2899
2023
Q2 		$1.58M Buy
1,318,680
+244,150
+23% +$304K ﹤0.01% 1574
2023
Q1 		$1.35M Sell
1,074,530
-234,277
-18% -$448K ﹤0.01% 1635
2022
Q4 		$2.84M Buy
1,308,807
+1,298,783
+12,957% +$10.7M ﹤0.01% 1347
2022
Q3 		$121K Buy
+10,024
New +$124K ﹤0.01% 2686

Other funds holding GOSS

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
KCM
Kalehua Capital Management Dallas, Texas $141M AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
AVM
Arch Venture Management Chicago, Illinois $677M AUM 322.07% 1-Year Est. Return
OCA
Octagon Capital Advisors New York $904M AUM 737.04% 1-Year Est. Return
SB
Samsara BioCapital Palo Alto, California $1.03B AUM 214.94% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
SL
Siren LLC Greenwich, Connecticut $3.61B AUM 203.3% 1-Year Est. Return

T. Rowe Price Associates's GOSS Position: Q1 2026 in Review

T. Rowe Price Associates increased its Gossamer Bio (GOSS) stake by 17% in Q1 2026, buying an estimated $29.7K and bringing the position to 132,026 shares worth $44K. The position accounts for ﹤0.01% of the portfolio, ranked #3077.

T. Rowe Price Associates first reported a position in GOSS in Q3 2022 and has held it in 14 quarters since. The position peaked at $6.35M in Q3 2024. 184 funds tracked by Wall St. Rank hold GOSS as of Q1 2026.

  • T. Rowe Price Associates held 132,026 shares of Gossamer Bio worth $44K as of Q1 2026.
  • T. Rowe Price Associates bought 18,888 Gossamer Bio shares in Q1 2026, an estimated $29.7K.
  • Gossamer Bio made up ﹤0.01% of T. Rowe Price Associates's portfolio in Q1 2026, its #3077 holding.
  • T. Rowe Price Associates first reported a position in Gossamer Bio in Q3 2022 and has held it in 14 quarters since.
  • T. Rowe Price Associates's Gossamer Bio position peaked at $6.35M in Q3 2024.
  • 184 funds tracked by Wall St. Rank held Gossamer Bio as of Q1 2026.

Based on T. Rowe Price Associates's 13F filing for Q1 2026, filed 15 May 2026.